File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A RANDOMIZED CONTROLLED TRIAL OF THE DIRECT RENIN INHIBITOR ALISKIREN IN NON-DIABETIC CKD

TitleA RANDOMIZED CONTROLLED TRIAL OF THE DIRECT RENIN INHIBITOR ALISKIREN IN NON-DIABETIC CKD
Authors
Issue Date2018
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
55th European Renal Association & European Dialysis and Transplant Association Congress (ERA-EDTA 2018), Copenhagen, Denmark, 24-27 May 2018. In Nephrology Dialysis Transplantation, 2018, v. 33 n. Suppl. 1, p. i21, abstract no. FP130 How to Cite?
AbstractINTRODUCTION AND AIMS: Aliskiren as an add-on therapy to losartan further reduced proteinuria among patients with diabetic nephropathy, yet the ALTITUDE study designed to investigate the potential renal protection benefits using this combination was prematurely terminated due to increased adverse events in the aliskiren arm. The potential long-term efficacy of aliskiren in non-diabetic chronic kidney disease (CKD) is unknown. METHODS: This open-label, prospective, randomized, controlled trial investigated the renoprotective potential and safety of aliskiren added to an angiotensin II receptor blocker in non-diabetic CKD stages 3-4 patients in a University teaching hospital in Hong Kong. Eligible patients receiving an ARB at the maximal dose were randomly assigned aliskiren or conventional treatment to achieve BP under 130/80 mmHg. The coprimary outcomes were doubling of baseline serum creatinine (sCr) or a 40% reduction in estimated glomerular filtration rate (eGFR); and incident end-stage renal disease (ESRD). Secondary endpoints included cardiovascular events, hyperkalemia and death. RESULTS: 76 patients were randomized: 37 to aliskiren (27 male, mean age 55.0±11.1 y), and 39 to control (27 male, mean age 55.0±9.4 y). There was no difference in baseline demographics, sCr (194±61 vs. 215±65 μmol/l, P=0.15), eGFR (31.9±9.0 vs. 27.7±9.0 ml/min/1.73m2, P=0.05), and urine protein-to-creatinine ratio for treatment vs. control subjects. After a follow-up of 144 weeks, four patients in intervention group and seven patients in control group reached the composite endpoint of doubling of sCr or ESRD (10.8% vs. 18.0%, P=0.377). The number of cardiovascular events was 4 (10.8%) vs. 1 (2.6 %), P=0.147. Hyperkalemia was encountered in 7 (18.9%) vs. 2 (5.1%) patients (P=0.063). There was no difference in the rate of eGFR change or proteinuria between the 2 groups. CONCLUSIONS: Aliskiren conferred no additional renoprotective benefit nor increased adverse events except for more hyperkalemia in non-diabetic CKD patients.
DescriptionPoster Session: Clinical nephrology 1
Persistent Identifierhttp://hdl.handle.net/10722/271981
ISSN
2019 Impact Factor: 4.531
2015 SCImago Journal Rankings: 1.780

 

DC FieldValueLanguage
dc.contributor.authorTang, SCW-
dc.contributor.authorChan, KW-
dc.contributor.authorIp, DKM-
dc.contributor.authorYap, YHD-
dc.contributor.authorMa, KMM-
dc.contributor.authorMok, MY-
dc.contributor.authorChan, GCW-
dc.date.accessioned2019-07-20T10:33:21Z-
dc.date.available2019-07-20T10:33:21Z-
dc.date.issued2018-
dc.identifier.citation55th European Renal Association & European Dialysis and Transplant Association Congress (ERA-EDTA 2018), Copenhagen, Denmark, 24-27 May 2018. In Nephrology Dialysis Transplantation, 2018, v. 33 n. Suppl. 1, p. i21, abstract no. FP130-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/271981-
dc.descriptionPoster Session: Clinical nephrology 1-
dc.description.abstractINTRODUCTION AND AIMS: Aliskiren as an add-on therapy to losartan further reduced proteinuria among patients with diabetic nephropathy, yet the ALTITUDE study designed to investigate the potential renal protection benefits using this combination was prematurely terminated due to increased adverse events in the aliskiren arm. The potential long-term efficacy of aliskiren in non-diabetic chronic kidney disease (CKD) is unknown. METHODS: This open-label, prospective, randomized, controlled trial investigated the renoprotective potential and safety of aliskiren added to an angiotensin II receptor blocker in non-diabetic CKD stages 3-4 patients in a University teaching hospital in Hong Kong. Eligible patients receiving an ARB at the maximal dose were randomly assigned aliskiren or conventional treatment to achieve BP under 130/80 mmHg. The coprimary outcomes were doubling of baseline serum creatinine (sCr) or a 40% reduction in estimated glomerular filtration rate (eGFR); and incident end-stage renal disease (ESRD). Secondary endpoints included cardiovascular events, hyperkalemia and death. RESULTS: 76 patients were randomized: 37 to aliskiren (27 male, mean age 55.0±11.1 y), and 39 to control (27 male, mean age 55.0±9.4 y). There was no difference in baseline demographics, sCr (194±61 vs. 215±65 μmol/l, P=0.15), eGFR (31.9±9.0 vs. 27.7±9.0 ml/min/1.73m2, P=0.05), and urine protein-to-creatinine ratio for treatment vs. control subjects. After a follow-up of 144 weeks, four patients in intervention group and seven patients in control group reached the composite endpoint of doubling of sCr or ESRD (10.8% vs. 18.0%, P=0.377). The number of cardiovascular events was 4 (10.8%) vs. 1 (2.6 %), P=0.147. Hyperkalemia was encountered in 7 (18.9%) vs. 2 (5.1%) patients (P=0.063). There was no difference in the rate of eGFR change or proteinuria between the 2 groups. CONCLUSIONS: Aliskiren conferred no additional renoprotective benefit nor increased adverse events except for more hyperkalemia in non-diabetic CKD patients.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.relation.ispartof55th ERA-EDTA CONGRESS-
dc.titleA RANDOMIZED CONTROLLED TRIAL OF THE DIRECT RENIN INHIBITOR ALISKIREN IN NON-DIABETIC CKD-
dc.typeConference_Paper-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.emailChan, KW: chriskwc@hku.hk-
dc.identifier.emailIp, DKM: dkmip@hku.hk-
dc.identifier.emailYap, YHD: desmondy@hku.hk-
dc.identifier.emailMa, KMM: h9914584@graduate.hku.hk-
dc.identifier.emailMok, MY: mmymok@hku.hk-
dc.identifier.emailChan, GCW: gcwchan1@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.identifier.authorityIp, DKM=rp00256-
dc.identifier.authorityYap, YHD=rp01607-
dc.identifier.doi10.1093/ndt/gfy104.FP130-
dc.identifier.hkuros299532-
dc.identifier.volume33-
dc.identifier.issueSuppl. 1-
dc.identifier.spagei21, abstract no. FP130-
dc.identifier.epagei21, abstract no. FP130-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats